Medical Research Council collaboration gives UK academia access to AstraZeneca compounds

In 2011, a novel agreement between the Medical Research Council (MRC) and AstraZeneca gave academic researchers across the UK unprecedented access to 22 of our clinical and preclinical compounds.

These compounds had stalled in early testing, often because they didn’t prove effective against the original target. But they may still be useful against other diseases. And because the compounds have already undergone some preliminary development, any new treatments arising from the research could reach patients faster. Fifteen studies are currently underway covering respiratory illness, muscular dystrophies, bone disease and various mental health conditions.